Synteract, an innovative CRO supporting biopharma companies in all phases of clinical development to bring new medicines to market, has conducted 4,000+ studies in 60+ countries, contributing to 240 product approvals, with centers of development in dermatology, neuroscience, oncology, pediatrics, general medicine, and rare & orphan indications.
Oncology - Synteract has managed 160+ oncology trials in the past 5 years: complex treatments like pathway-targeted therapies, chemotherapy, immunotherapy, cell-based and gene therapies. We were one of the first CROs to work in immunotherapy over 11 years ago.
Pediatrics – We’ve conducted 310+ pediatric trials globally, in 25+ indications. Our pediatric cross-functional team helps clients navigate complex research to allow medicines to serve the littlest ones.
Dermatology – A leading dermatology CRO, we support novel and in-demand dermatology drug development, having conducted 270+ derm trials, in 30+ indications of disease and skin care products.
Neuroscience – We’ve managed 130+ neuroscience trials in the past 5 years, including neuro-degenerative, psychiatric and pain indications, with extensive experience in drugs for Alzheimer’s, Parkinson’s, ALS, MS, migraine, schizophrenia, more.
General medicine – With a wealth of experience over 30 years, there are many therapeutic areas in which Synteract has proven expertise, notably women’s health and gastroenterology.
Rare & Orphan – We’ve conducted 130+ trials in rare & orphan diseases in the past 5 years, specializing in unique studies that affect few, and requiring multidisciplinary approaches.
Learn how we support your clinical trials. Contact us today: www.synteract.com